ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. for securities fraud, with a class period from May 20, 2024, to January 9, 2026, and investors are encouraged to participate as lead plaintiffs [1][5]. Group 1: Lawsuit Details - The lawsuit alleges that Atara made false and misleading statements regarding manufacturing issues and regulatory prospects related to the tabelecleucel Biologics License Application (BLA), which could negatively impact the company's business and financial condition [5]. - Investors who purchased Atara securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation, and the deadline to move the Court for this role is May 22, 2026 [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field, including being ranked No. 1 for the number of securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].